Experience

Davis Polk represents a global pharmaceutical company in connection with a congressional drug-pricing investigation by the Senate Finance and House Oversight and Reform Committees.

Davis Polk advised the initial purchasers in connection with the offering by Corporación Nacional del Cobre de Chile of $1.3 billion aggregate principal amount of its 4.375% notes due 2049…

Davis Polk is advising PT Aplikasi Karya Anak Bangsa (“GOJEK”) on its ongoing Series F preferred share funding round, with an initial closing led by Google, JD.com, Tencent, Mitsubishi…

We advised the committee following the abandonment of a multi-billion-dollar nuclear project

Davis Polk advised the initial purchaser in connection with a $100 million Regulation S offering by Fantasia Holdings Group Co., Limited of its 15.000% senior notes due 2021 to be…

Davis Polk advised the initial purchasers in connection with a $500 million 6.875% Regulation S notes offering by Fortune Star (BVI) Limited, a wholly owned subsidiary of Fosun…

Davis Polk advised the underwriters in connection with a public offering by International Business Machines Corporation of €1.75 billion principal amount of its 0.375% notes due 2023, …

Davis Polk advised the underwriters on an SEC-registered offering on Schedule B by Oesterreichische Kontrollbank Aktiengesellschaft of its $1.5 billion 2.625% guaranteed global notes…

Davis Polk advised the initial purchasers in connection with the $200 million Regulation S offering by Central China Real Estate Limited of its 7.325% senior notes due 2020. CCRE is a…

Davis Polk advised the underwriters in connection with the offering of $2.5 billion aggregate principal amount of 3.050% bonds due January 29, 2024, issued by the Province of Ontario…